Market Place
Sourcing Support
Actinogen Randomize 1st US Participant in XanaMIA Alzheimer`s Trial
09 Dec 2024 //
PR NEWSWIRE
Actinogen Reports Positive Depression Results In XanCIDD Phase 2a Trial
27 Aug 2024 //
PR NEWSWIRE
Australian biotech`s cortisol blocker fails to improve in ph 2 depression
12 Aug 2024 //
FIERCE BIOTECH
Australian Biotech`s Cortisol Blocker Fails In Phase 2 Depression Study
12 Aug 2024 //
FIERCE BIOTECH
Actinogen`s Xanamem Shows Significant Results In Depression Trial
12 Aug 2024 //
PR NEWSWIRE
Xanamem® Biomarker Trial Shows Potential Efficacy In Alzheimer`s Disease
26 Jun 2024 //
PR NEWSWIRE
Actinogen XanaCIDD Phase 2a Cognition, Depression Trial Completes Enrollment
22 Apr 2024 //
PR NEWSWIRE
First Patient Dosed In Actinogen`s XanaMIA Alzheimer`s Phase 2b
15 Apr 2024 //
PR NEWSWIRE
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum
13 Oct 2023 //
PR NEWSWIRE
Actinogen optimizes XanaMIA Phase 2b Alzheimer`s disease trial design
26 Sep 2023 //
PR NEWSWIRE
Actinogen to present progress on Cognitive Impairment Phase 2 trials
31 May 2023 //
PR NEWSWIRE
Actinogen presents positive Phase 2a Xanamem data in at ADPD
30 Mar 2023 //
PR NEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.